- Pulse Biosciences ( NASDAQ: PLSE ) said the U.S. Food and Drug Administration (FDA) granted 510(k) clearance of expanded energy settings for use with CellFX System treatments tips in dermatology.
- CellFX system is used to remove certain skin lesions, growths, and bumps.
- Clinicians in the U.S. are now able to access broader treatment settings to provide more customized energy delivery specific to individual lesions,” said Pulse President and CEO Darrin Uecker
- PLSE +9.43% to $1.74 premarket Aug. 4.
For further details see:
Pulse stock rises 9% as FDA clears added energy settings for use with skin treatment device CellFX